Kyorin in-licenses sleep apnea treatment from Bayer
Dec 17, 2024 · Japanese drugmaker Kyorin Pharmaceutical (TYO: 4569) has entered into a licensee agreement with Bayer (BAYN: DE) for the novel obstructive sleep apnea (OSA) …
Second FDA approval for BeiGene’s Tevimbra in 2024
Dec 27, 2024 · The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for …
Pfizer unveils new China strategy with $1 billion investment
Nov 8, 2024 · Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with China’s “Healthy China 2030” initiative. This includes an …
PDUFA target action date for Soleno’s DCCR extended by three …
Nov 27, 2024 · The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ (Nasdaq: SLNO) the New Drug Application (NDA) for DCCR (diazoxide …
Pharma, Biotech and Generics Industry News | The Pharmaletter
Jan 21, 2025 · Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results from a Phase Ib/IIa clinical trial with amycretin …
Mixed results for GSK’s Zejula/Jemperli combo
Dec 20, 2024 · UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula (niraparib) and Jemperli (dostarlimab) in first …
FDA tests let military use expired drugs
Apr 5, 2000 · This article is accessible to registered users, to continue reading please register for free.. A free trial will give you access to exclusive features, interviews, round-ups and …
Pharma USA 2025 - The Pharmaletter
The two day event offers a variety of means for networking and collaboration: Hackathons offering a hyper-interactive session where attendees work as a team to hack strategic issues.
FDA panel flags risks as AstraZeneca seeks full Andexxa approval
Nov 22, 2024 · AstraZeneca faces challenges in securing full FDA approval for Andexxa, its anticoagulant reversal therapy, due to safety concerns raised during an advisory committee …
Uncertain future for S1P receptor modulators in Crohn’s disease, …
Oct 11, 2024 · Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG Week 2024. The results show modest efficacy in …